Skip to content
2000
Volume 3, Issue 2
  • ISSN: 2212-3962
  • E-ISSN: 1574-8901

Abstract

Conivaptan, a dual vasopressin receptor antagonist, is a member of an emerging class of medications for the treatment of euvolemic hyponatremia. These agents induce a free-water diuresis as compared to the natriuretic effect of loop diuretics and make them an intriguing prospect for the treatment of congestive heart failure. Article also includes recent patents on this topic.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/prc/10.2174/157489008784705403
2008-06-01
2025-10-04

  • From This Site

    /content/journals/prc/10.2174/157489008784705403
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/prc/10.2174/157489008784705403
Loading

  • Article Type:     Research Article
Keyword(s): aquaretic; congestive heart failure; Conivaptan; vasopressin receptor antagonists
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test